[1] Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections[J]. Lancet Infect Dis, 2011, 11(2):142-151.
[2] Xiao M, Chen SC, Kong F, et al. Five-year China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study of invasive fungal infections caused by noncandidal yeasts:species distribution and azole susceptibility[J]. Infect Drug Resist, 2018, 11:1659-1667.
[3] Villar JM, Velasco CG, Delgado JD. Fungemia due to Rhodotorula mucilaginosa in an immunocompetent, critically ill patient[J]. J Infect Chemother, 2012, 18(4):581-583.
[4] Ioannou P, Vamvoukaki R, Samonis G. Rhodotorula species infections in humans:A systematic review[J]. Mycoses, 2019, 62(2):90-100.
[5] Borman AM, Muller J, Walsh-Quantick J, et al. Fluconazole resistance in isolates of uncommon pathogenic yeast species from the United Kingdom[J]. Antimicrob Agents Chemother, 2019, 63(8).
[6] Guidara R, Trabelsi H, Neji S, et al. Rhodotorula fungemia:Report of two cases in Sfax (Tunisia)[J]. J Mycol Med, 2016, 26(2):178-181.
[7] Potenza L, Chitasombat MN, Klimko N, et al. Rhodotorula infection in haematological patient:Risk factors and outcome[J]. Mycoses, 2019, 62(3):223-229.
[8] Pereira C, Ribeiro S, Lopes V, et al. Rhodotorula mucilaginosa Fungemia and pleural tuberculosis in an immunocompetent patient:an uncommon association[J]. Mycopathologia, 2016, 181(1-2):145-149.
[9] Nunes JM, Bizerra FC, Ferreira RC, et al. Molecular identification, antifungal susceptibility profile, and biofilm formation of clinical and environmental Rhodotorula species isolates[J]. Antimicrob Agents Chemother, 2013, 57(1):382-389.
[10] Arendrup MC, Boekhout T, Akova M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections[J]. Clin Microbiol Infect, 2014, 20(Suppl 3):76-98.
[11] Tuon FF, Costa SF. Rhodotorula infection. A systematic review of 128 cases from literature[J]. Rev Iberoam Micol, 2008, 25(3):135-140.
[12] Mohd Nor F, Tan LH, Na SL, et al. Meningitis caused by Rhodotorula mucilaginosa in HIV-infected patient:a case report and review of the literature[J]. Mycopathologia, 2015, 180(1-2):95-98.
[13] Hsiue HC, Huang YT, Kuo YL, et al. Rapid identification of fungal pathogens in positive blood cultures using oligonucleotide array hybridization[J]. Clin Microbiol Infect, 2010, 16(5):493-500.
[14] De Almeida GM, Costa SF, Melhem M, et al. Rhodotorula spp. isolated from blood cultures:clinical and microbiological aspects[J]. Med Mycol, 2008, 46(6):547-556.
[15] Xiao M, Sun ZY, Kang M, et al. Five-year national surveillance of invasive candidiasis:species distribution and azole susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study[J]. J Clin Microbiol, 2018, 56(7):e00577-18.
[16] Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance:prevalence, mechanisms, and management[J]. Lancet Infect Dis, 2017, 17(12):e383-e392.
[17] Desnos-Ollivier M, Bretagne S, Boullie A, et al. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017)[J]. Clin Microbiol Infect, 2019, 25(5):e631-634.
[18] Spader TB, Ramirez-Castrillon M, Valente P, et al. In vitro interactions of amphotericin B combined with non-antifungal agents against Rhodotorula mucilaginosa strains[J]. Mycopathologia, 2019, 184(1):35-43.
[19] Libkind D.[J]. Rev Argent Microbiol, 2007, 39(3):133-137.
[20] Saracli MA, Sener K, Gonlum A, et al. Genotyping of clinical Rhodotorula mucilaginosa isolates by pulsed field gel electrophoresis[J]. Mycoses, 2003, 46(11-12):487-491.
[21] Lunardi LW, Aquino VR, Zimerman RA, et al. Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital[J]. Clin Infect Dis, 2006, 43(6):e60-63.
[22] Bretagne S, Renaudat C, Desnos-Ollivier M, et al. Predisposing factors and outcome of uncommon yeast species-related fungaemia based on an exhaustive surveillance programme (2002-14)[J]. J Antimicrob Chemother, 2017, 72(6):1784-1793.
[23] Capoor MR, Aggarwal S, Raghvan C, et al. Clinical and microbiological characteristics of Rhodotorula mucilaginosa infections in a tertiary-care facility[J]. Indian J Med Microbiol, 2014, 32(3):304-309.
[24] Falces-Romero I, Cendejas-Bueno E, Romero-Gomez MP, et al. Isolation of Rhodotorula mucilaginosa from blood cultures in a tertiary care hospital[J]. Mycoses, 2018, 61(1):35-39.